Web1 aug. 2014 · In this paper, we reviewed the current literature on induction chemotherapy for mesothelioma as well as described the SMART protocol and upcoming studies of … Webbenefit for neoadjuvant chemotherapy was only found in patients with neuroendocrine tumors (hazard ratio, 0.49; 95% CI, 0.33-0.74 [P5.001]). CONCLUSIONS: Patients with neuroendocrine tumors benefit from neoadjuvant chemotherapy, as evidenced by better overall survival and lower rates of non-organ-confined disease at the time of RC.
Survival Outcomes for Induction vs Adjuvant Chemotherapy in ... - PubMed
Web28 apr. 2024 · Malignant pleural mesothelioma (MPM) is a poor prognosis disease, patients who are deemed eligible for resection usually are submitted to a multimodal therapy … Web1 jan. 2024 · Neoadjuvant pemetrexed plus cisplatin was administered, followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT), to assess the … newtown centre of classical ballet \\u0026 voice
Frontiers Neoadjuvant Treatment in Patients With Resectable …
WebInduction Therapy for Mesothelioma One particular approach of multimodality treatment for mesothelioma is induction therapy followed by surgery. Among its several advantages, the most important is downstaging of the tumor into a resectable stage, although morbidity and mortality might be increased. In this article we review the princ … Web9 jun. 2024 · The KM curves based on the log-rank test did not show any significant difference in the median OS of patients who received neoadjuvant immunotherapy compared to adjuvant immunotherapy (Fig. 1).The median OS of patients who received neoadjuvant immunotherapy was 26.78 months (CI: 23.92–31.24) vs. 34.37 months (CI: … new town center in jacksonville fl